Phase I Study of LBH589, A Novel Oral Deacetylase Inhibitor in Patients with Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma

Title Phase I Study of LBH589, A Novel Oral Deacetylase Inhibitor in Patients with Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma

Contact TH

Principal Investigator Myron Czuczman, MD

Study Number 147408

Phase1

Summary

The purpose of this study is to find out the effects of a drug called LBH589 when given to people with recurrent or refractory Hodgkin or Non-Hodgkin's lymphoma. The safety of this drug will also be studied. The participant’s physical state, changes in the size of the tumor, or state of Hodgkin or non-Hodgkin's Lymphoma, and laboratory findings taken while on-study will help the researchers decide if LBH589 is safe and effective.

Eligibility

Inclusion Criteria:

Age 18 or over
Diagnosis of relapse/refractory Hodgkin Lymphoma or NHL
Lab results within normal limits, unless due to bone marrow involvement with lymphoma

Exclusion Criteria:

Prior HDAC or valproic acid cancer treatment
Impaired Cardiac or GI Function

For more information about the clinical study go to Clinicaltrial.Gov